Abstract
In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Current Pharmaceutical Design
Title:Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations
Volume: 24 Issue: 28
Author(s): Linh Tran*
Affiliation:
- Computational Chemistry Research Group, Ton Duc Thang University, Ho Chi Minh, City,Vietnam
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Abstract: In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Tran Linh *, Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations, Current Pharmaceutical Design 2018; 24 (28) . https://dx.doi.org/10.2174/1381612824666180813093420
DOI https://dx.doi.org/10.2174/1381612824666180813093420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fat Tissue Distribution Changes in HIV-Infected Patients Treated with Lopinavir/Ritonavir. Results of the MONARK Trial
Current HIV Research A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Mini-Reviews in Medicinal Chemistry ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Imino-Sugar-Based Nucleosides
Current Topics in Medicinal Chemistry Thymulin: An Emerging Anti-Inflammatory Molecule
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Journal Current Genomics: News and Editorial Prospects
Current Genomics Coffee and Caffeine Effects on Hypertension
Current Hypertension Reviews Benzimidazole Derivatives as Kinase Inhibitors
Current Medicinal Chemistry Animal Models of Narcolepsy
CNS & Neurological Disorders - Drug Targets Maintenance Treatment of Opioid Dependence and Patterns of Non-Prescribed Drug Use: Results of a 4-Year Trial
Letters in Drug Design & Discovery Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-β Pathology in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research Development of Molecular Probes for Imaging Sigma-2 Receptors in Vitro and in Vivo
Central Nervous System Agents in Medicinal Chemistry Study on the Development of a Cyclohexane Based Tripodal Molecular Device as "OFF-ON-OFF" pH Sensor and Fluorescent Iron Sensor
Current Analytical Chemistry Medicinal Plants for the Treatment of Hair Loss and the Suggested Mechanisms
Current Pharmaceutical Design Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Direct and Rapid Transcript Analysis Assay for CYP mRNA Expression and Inducibility in Human Primary Hepatocytes
Drug Metabolism Letters Depression and Mania in Bipolar Disorder
Current Neuropharmacology Subject Index To Volume 6
Current Gene Therapy Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design